ORAGENICS INC (OGEN) earnings date, results and what the price requires
NYSE · SEC CIK 0001174940 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 13, 2026 | — | $-2.5M | $-0.57 | Filing |
| Mar 31, 2026 | May 8, 2026 | — | $-2.2M | $-0.51 | Filing |
| Dec 31, 2025 | Mar 16, 2026 | — | $-976.7M | $4.15 | Filing |
| Sep 30, 2025 | Nov 7, 2025 | — | $-3.1M | $-1.96 | Filing |
| Jun 30, 2025 | Aug 8, 2025 | — | $-2.3M | $-3.10 | Filing |
| Mar 31, 2025 | May 9, 2025 | — | $-2.2M | $-3.65 | Filing |
| Dec 31, 2024 | Mar 14, 2025 | — | $-1.05B | $-20.59 | Filing |
| Sep 30, 2024 | Nov 13, 2024 | — | $-2.5M | $-11.32 | Filing |
What would ORAGENICS INC have to report for its valuation to change?
At $0.43, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -49.3% a year, to $0.04. On that path the next quarter needs diluted EPS near $-0.99, against $-1.96 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -49.3% | -49.3% |
| EPS needed in final year | $0.04 | $0.04 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. OGEN goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.